Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06951880 | A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers | PHASE1 | NOT YET_RECRUITING | 178 | — | — | Jun 27, 2025 | Sep 24, 2026 | Apr 30, 2025 | 1 | United Kingdom |
The safety and tolerability of AZD4916 following oral administration of single-ascending doses and multiple-ascending doses to healthy participants (including Japanese and Chinese) will be assessed.
| Arm | Type | Description |
|---|---|---|
| AZD4916 | EXPERIMENTAL | Parts 1a and 2a participants will receive a single oral dose of AZD4916 on Day 1. Parts 1b and 2b participants will receive a single oral dose of AZD4916 on Day 1 and multiple doses of AZD4916 on Days 4 through 17. |
| Placebo | PLACEBO_COMPARATOR | Parts 1a and 2a participants will receive a single oral dose of placebo on Day 1. Parts 1b and 2b participants will receive a single dose placebo on Day 1 and multiple doses of placebo on Days 4 through 17. |
| Name | Type | Description |
|---|---|---|
| AZD4916 | DRUG | AZD4916 will be administered as oral solution. |
| Placebo | OTHER | Placebo will be administered as oral solution. |
Main Inclusion Criteria: * Healthy male and female participants with suitable veins for cannulation or repeated venipuncture. * All females must have negative pregnancy test and females of childbearing potential must not be lactating and must agree to use an approved method of highly effective cont...